

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2024/107646 A8

(43) International Publication Date
23 May 2024 (23.05.2024)

(51) International Patent Classification:

C07K 14/44 (2006.01) C07K 14/725 (2006.01)
A61K 39/00 (2006.01) C07K 14/705 (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/US2023/079508

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

13 November 2023 (13.11.2023)

(48) Date of publication of this corrected version:

26 September 2024 (26.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/383,654 14 November 2022 (14.11.2022) US

(15) Information about Correction:

see Notice of 26 September 2024 (26.09.2024)

(71) Applicant: **CARIBOU BIOSCIENCES, INC.** [US/US];
2929 7th Street, Suite 105, Berkeley, CA 94710 (US).

(72) Inventors: **EDWARDS, Leslie**; 3003 Cedarwood Loop,
San Ramon, CA 94582 (US). **KANNER, Steven B.**; 610 S
Van Ness Avenue, Unit 1, Los Angeles, CA 90005 (US).
KELLY, Erin K.; 2718 Dana Street, Berkeley, CA 94705
(US). **NAMBURI, Sai Valli Srujana**; 1750 Rheem Av-
enue, Richmond, CA 94801 (US).

(74) Agent: **ZIMMERMAN, Olga**; Caribou Biosciences, Inc.,
2929 7th Street, Suite 105, Berkeley, CA 94710 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-CLL-1 CHIMERIC ANTIGEN RECEPTORS, ENGINEERED CELLS AND RELATED METHODS

(57) Abstract: An anti-CD371 (anti-CLL-1) chimeric antigen receptor (CAR), engineered immune cells comprising the CAR, as well as therapeutic compositions, therapeutic methods and companion diagnostic methods are disclosed herein.

WO 2024/107646 A8